Option 3: Switching to Tirzepatide Another option for patients who are not achieving their weight loss goals on certain GLP-1s, like Semaglutide, is switching to Tirzepatide, a newer dual-action GLP-1 and GIP receptor agonist that has shown more impressive weight loss results in recent clinical trials
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP
Users can expect to see initial results within days or weeks, with more significant transformations occurring over 3 to 6 months of consistent use
Four separate peptides in one vial means four separate opportunities for impurity, mislabeling, endotoxin, or degradation risks that are entirely about sourcing and manufacturing and have nothing to do with the molecules intrinsic biology